Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan
Authors:
Open Access
- 20 April 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-12
Abstract
The spreading of viral hepatitis among injecting drug users (IDU) is an emerging public health concern. This study explored the prevalence and the risks of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) among IDU-dominant prisoners in Taiwan. HBV surface antigen (HBsAg), antibodies to HCV (anti-HCV) and HDV (anti-HDV), viral load and HCV genotypes were measured in 1137(67.0%) of 1697 prisoners. 89.2% of participants were IDUs and none had HIV infection. The prevalence of HBsAg, anti-HCV, dual HBsAg/anti-HCV, HBsAg/anti-HDV, and triple HBsAg/anti-HCV/anti-HDV was 13.6%, 34.8%, 4.9%, 3.4%, and 2.8%, respectively. HBV viremia rate was significantly lower in HBV/HCV-coinfected than HBV mono-infected subjects (66.1% versus 89.9%, adjusted odds ratio/95% confidence intervals [aOR/CI] = 0.27/0.10–0.73). 47.5% anti-HCV-seropositive subjects (n = 396) were non-viremic, including 23.2% subjects were antivirals-induced. The predominant HCV genotypes were genotype 6(40.9%), 1a(24.0%) and 3(11.1%). HBsAg seropositivity was negatively correlated with HCV viremia among the treatment naïve HCV subjects (44.7% versus 72.4%, aOR/CI = 0.27/0.13–0.58). Anti-HCV seropositivity significantly increased the risk of anti-HDV-seropositivity among HBsAg carriers (57.1% versus 7.1%, aOR/CI = 15.73/6.04–40.96). In conclusion, IUDs remain as reservoirs for multiple hepatitis viruses infection among HIV-uninfected prisoners in Taiwan. HCV infection increased the risk of HDV infection but suppressed HBV replication in HBsAg carriers. An effective strategy is mandatory to control the epidemic in this high-risk group.Keywords
Funding Information
- Taiwan Liver Research Foundation
- Kaohsiung Medical University (KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3, KMU-DK107004; MOST 108-2314-B-037-066-MY3)
- Kaohsiung Medical University Hospital (KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05, KMUH-DK109005~1; KMUH-DK109002; KMUH-108-8R05)
- Center for Cancer Research of Kaohsiung Medical University (KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3, KMU-TC108A04-3)
- Liquid Biopsy and Cohort Research Center of Kaohsiung Medical University (KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05, KMU-TC109B05)
This publication has 47 references indexed in Scilit:
- Minimization of hepatitis B infection by a 25-year universal vaccination programJournal of Hepatology, 2012
- Molecular Epidemiology of Hepatitis D Virus Infection among Injecting Drug Users with and without Human Immunodeficiency Virus Infection in TaiwanJournal of Clinical Microbiology, 2011
- Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based StudyThe Kaohsiung Journal of Medical Sciences, 2010
- Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full‐length sequences of two new subtype 6w strains and a recombinant form_2b6wJournal of Medical Virology, 2009
- Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA geneJournal of General Virology, 2009
- Treatment of chronic hepatitis C in Asia: When East meets WestJournal of Gastroenterology and Hepatology, 2009
- Extremely High Prevalence and Genetic Diversity of Hepatitis C Virus Infection among HIV‐Infected Injection Drug Users in TaiwanClinical Infectious Diseases, 2008
- Epidemiology and risk factors for hepatitis C in Alaska NativesHepatology, 2004
- Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in TaiwanJournal of Medical Virology, 2001
- Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infectionsJournal of Viral Hepatitis, 2000